Threshold Pharmaceuticals Inc. (NASDAQ:THLD) – William Blair lifted their FY2016 earnings per share (EPS) estimates for shares of Threshold Pharmaceuticals in a research note issued to investors on Monday. William Blair analyst J. Sonnier now forecasts that the firm will post earnings per share of ($0.37) for the year, up from their previous forecast of ($0.38). William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Threshold Pharmaceuticals’ FY2017 earnings at ($0.24) EPS, FY2018 earnings at ($0.25) EPS and FY2019 earnings at ($0.26) EPS.

Separately, S&P Equity Research lowered their price objective on shares of Threshold Pharmaceuticals from $0.67 to $0.52 in a research report on Friday, September 30th.

Earnings History and Estimates for Threshold Pharmaceuticals (NASDAQ:THLD)

Shares of Threshold Pharmaceuticals (NASDAQ:THLD) opened at 0.481 on Wednesday. Threshold Pharmaceuticals has a 52-week low of $0.21 and a 52-week high of $4.36. The company has a 50-day moving average price of $0.58 and a 200 day moving average price of $0.62. The firm has a market capitalization of $34.40 million, a PE ratio of 0.812 and a beta of 4.78.

Threshold Pharmaceuticals (NASDAQ:THLD) last posted its earnings results on Monday, November 7th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01.

Institutional investors have recently added to or reduced their stakes in the company. Spark Investment Management LLC purchased a new position in Threshold Pharmaceuticals during the third quarter worth about $114,000. Oxford Asset Management boosted its position in Threshold Pharmaceuticals by 746.7% in the second quarter. Oxford Asset Management now owns 202,522 shares of the biotechnology company’s stock worth $129,000 after buying an additional 178,602 shares during the period. Paloma Partners Management Co purchased a new position in Threshold Pharmaceuticals during the second quarter worth about $152,000. Citadel Advisors LLC boosted its position in Threshold Pharmaceuticals by 113.1% in the third quarter. Citadel Advisors LLC now owns 286,419 shares of the biotechnology company’s stock worth $194,000 after buying an additional 151,988 shares during the period. Finally, KCG Holdings Inc. purchased a new position in Threshold Pharmaceuticals during the third quarter worth about $238,000. Hedge funds and other institutional investors own 28.16% of the company’s stock.

About Threshold Pharmaceuticals

Threshold Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.

5 Day Chart for NASDAQ:THLD

Receive News & Stock Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.